Emerging Biopharma
We Are Immersed In A New Era Of Drug Discovery – And A Revolution In Financing.
Locust Walk links visionary investors and partners with transformative opportunities in emerging biopharma – while providing vital leadership and deal acumen for company growth.
Tomorrow’s great pharmaceutical breakthroughs will come from today’s emerging biopharma firms. At a time when the growth of large pharmaceutical companies is stalling, a wave of scientific discovery is fueling the rise of a new class of biopharma firms.
These young firms must carve a new path, as a decade of poor returns for the asset class has reduced the amount of traditional institutional venture capital available.
Enter Locust Walk.
Our seasoned industry executives contribute specific, relevant operating experience – empowering small biopharma companies by providing them with hands-on expertise, connectivity with potential funding sources and strategic partners, and deep analytical capability. We are distinguished by our rigorous assessment of commercial value and by the continuity we foster – paralleling process discussions with strategic partners and potential investors to maximize options for companies.
Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.
Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.
Business & Corporate Development
Financing & IPO Advisory
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
OVERVIEW
- Commercial assessment
- Investor materials preparation
- Targeted investor outreach
- Due diligence staging
- Deal comparables
- Introductions to bankers and research analysts
- S1 drafting (business section)
RESULTS
- Robust understanding of opportunity
- Succinct presentations
- Relevant Investors
- Competitive process
- Realistic valuation and optimal outcome
Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.
Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.
Business & Corporate Development
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
Business & Corporate Development
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
Financing & IPO Advisory
OVERVIEW
- Commercial assessment
- Investor materials preparation
- Targeted investor outreach
- Due diligence staging
- Deal comparables
- Introductions to bankers and research analysts
- S1 drafting (business section)
Financing & IPO Advisory
RESULTS
- Robust understanding of opportunity
- Succinct presentations
- Relevant Investors
- Competitive process
- Realistic valuation and optimal outcome
Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.
Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.
Business & Corporate Development
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
Financing & IPO Advisory
OVERVIEW
- Commercial assessment
- Investor materials preparation
- Targeted investor outreach
- Due diligence staging
- Deal comparables
- Introductions to bankers and research analysts
- S1 drafting (business section)
RESULTS
- Robust understanding of opportunity
- Succinct presentations
- Relevant Investors
- Competitive process
- Realistic valuation and optimal outcome
Emerging Biopharma Transaction Highlights
CLIENT: Thar Pharmaceuticals
TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition
CLIENT: Strongbridge Biopharma
PARTNER: Investors
TRANSACTION:
Private Placement of $26.4M
CLIENT: Fabrus
PARTNER: Senesco
TRANSACTION:
Merger between Fabrus and Senesco Technologies
CLIENT: Strategic Science & Technologies, LLC
PARTNER: Undisclosed
TRANSACTION:
Worldwide Licensing Agreement for IbuCream (topical ibuprofen)
CLIENT: Strongbridge Biopharma
TRANSACTION:
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share
CLIENT: Strategic Science & Technologies, LLC
PARTNER: Global OTC Player
TRANSACTION:
US Option Agreement for IbuCream (topical ibuprofen)
CLIENT: Ascenta
PARTNER: Debiopharm Group
TRANSACTION:
Worldwide Licensing Agreement for AT-406
CLIENT: Concordia Pharmaceuticals
PARTNER: Ono
TRANSACTION:
Licensing Agreement for Salirasib in Japan
CLIENT: Strongbridge Biopharma
PARTNER: Investors
TRANSACTION:
Private Placement of $33.2M
CLIENT: TesoRx
PARTNER: Aspen
TRANSACTION:
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.
CLIENT: Angiochem
PARTNER: Geron
TRANSACTION: Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase
CLIENT: Synthetic Genomics
PARTNER: Novartis
TRANSACTION:
Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring